Table 2.

Univariate analysis by Cox regression of factors associated with disease outcomes in patients with ES treated with neoadjuvant chemotherapy and R0 resection

Covariate	Local control (12 events)			Progression-free survival (28 events)			Overall survival (21 events)
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Age, per 1 year	1.02	0.97–1.08	0.497	1.04	1.01–1.08	0.022	1.06	1.02–1.10	0.002
Male sex	0.95	0.26–3.52	0.942	1.07	0.47–2.44	0.865	0.91	0.33–2.47	0.905
Metastasis at presentation	4.55	1.18–17.6	0.028	4.31	1.83–10.1	0.001	6.02	2.43–14.9	<0.001
Extremity location	0.39	0.11–1.43	0.154	1.39	0.66–2.95	0.385	1.20	0.51–2.85	0.680
No. chemotherapy cycles	1.05	0.81–1.35	0.730	1.06	0.90–1.25	0.497	0.96	0.76–1.23	0.772
Initial tumor size, per cm	1.02	0.99–1.04	0.169	1.01	1.00–1.02	0.132	1.01	1.00–1.03	0.110
Post-chemotherapy tumor size, per cm	1.00	0.99–1.02	0.705	1.01	1.00–1.02	0.085	1.01	1.00–1.02	0.155
PR by RECIST	1.26	0.32–5.05	0.743	0.46	0.16–1.26	0.131	0.59	0.18–1.92	0.381
Initial tumor volume, per 10 cm3	1.02	1.00–1.04	0.045	1.01	0.99–1.02	0.380	1.01	0.99–1.03	0.224
Post-chemotherapy tumor volume, per 10 cm3	1.00	0.93–1.07	0.988	1.03	1.00–1.07	0.064	1.04	1.00–1.08	0.059
Volume reduction > 75%	1.49	0.36–6.25	0.583	0.54	0.21–1.37	0.196	0.81	0.27–2.41	0.701
Necrosis ≤ 95%	5.92	1.59–21.7	0.008	3.04	1.42–6.54	0.004	2.90	1.20–6.99	0.018

HR: hazard ratio; CI: confidence interval; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors